The Future of GLP-1: What's Coming in 2026 and Beyond

The GLP-1 medication landscape is evolving at a pace rarely seen in pharmaceutical development. What started as a diabetes treatment has become the most active area of drug development in medicine. Here's what's in the pipeline and what it means for patients.

Oral Semaglutide for Weight Loss

Novo Nordisk's oral semaglutide (Rybelsus) is already approved for type 2 diabetes, but at doses too low for significant weight loss. The higher-dose oral formulation — tested at 25mg and 50mg daily — has shown remarkable results:

• The OASIS 1 trial showed 17.4% weight loss with oral semaglutide 50mg over 68 weeks
• This approaches the efficacy of injectable Wegovy without needles
• FDA approval for the weight-management indication is expected in 2026

The implications are significant. Many patients avoid GLP-1 medications specifically because of injection anxiety. An equally effective oral option could dramatically expand the patient population.

Next-Generation Multi-Agonists

If semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GLP-1 and GIP), the next frontier is three — and beyond.

Retatrutide (Eli Lilly)

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trial data was striking:

• 24.2% average weight loss at the highest dose over 48 weeks
• Some participants lost over 30% of their body weight
• Phase 3 trials are underway with results expected in late 2026

Survodutide (Boehringer Ingelheim)

A dual GLP-1/glucagon agonist showing promise not only for weight loss but particularly for non-alcoholic steatohepatitis (NASH) — fatty liver disease. Phase 2 data showed significant liver fat reduction alongside substantial weight loss.

Amycretin (Novo Nordisk)

A novel dual amylin/GLP-1 agonist. Early Phase 1 data showed 13.1% weight loss in just 12 weeks — an unprecedented rate that, if confirmed in larger trials, would represent a meaningful leap in efficacy.

Combination Therapies

Researchers are increasingly exploring GLP-1 medications combined with other agents:

• GLP-1 + muscle-sparing agents: Bimagrumab, a myostatin inhibitor, is being studied alongside semaglutide to preserve lean mass during weight loss. Early results are promising.
• GLP-1 + SGLT2 inhibitors: Combining incretin-based therapies with drugs like empagliflozin may provide additive cardiometabolic benefits.
• GLP-1 + behavioral interventions: The STEP 3 trial demonstrated that intensive behavioral therapy combined with semaglutide produced greater weight loss than either alone.

We are likely in the early innings of the GLP-1 era, not the late innings. The medications available today — as effective as they are — may look modest compared to what's coming in the next 5-10 years.

The Access Challenge

More effective medications mean nothing if patients can't access them. The industry faces several headwinds:

• Cost: Next-generation medications will likely launch at premium prices
• Manufacturing: Scaling production of injectable peptides is non-trivial — the shortages of 2023-2024 demonstrate this
• Insurance: Payers are already struggling with the cost burden of current GLP-1s. Adding more expensive options will intensify the coverage debate.
• Patent cliffs: Semaglutide patents begin expiring in the late 2020s, potentially opening the door to generic versions and lower prices

What This Means for Patients Today

If you're considering GLP-1 therapy now, the pipeline shouldn't necessarily cause you to wait. Current medications are highly effective and well-understood. However, it's worth knowing that:

• Oral options are coming soon for those who dislike injections
• Even more effective medications are on the horizon
• The muscle-loss problem is being actively addressed
• Prices are more likely to decrease than increase over the coming years